Texas is positioning itself as a national leader in psychedelic research after lawmakers approved $50 million to support clinical trials studying ibogaine, a psychoactive compound derived from a West African plant. The funding, tied to Senate Bill 2308 and expected to be signed by Governor Greg Abbott, establishes a research consortium involving universities, hospitals, and drug developers to evaluate ibogaine as a potential treatment for addiction, traumatic brain injury, and related conditions.
The effort follows growing interest among veterans and policymakers who believe the compound may offer new treatment possibilities for trauma and substance use disorders. Former Texas Governor Rick Perry has been a prominent advocate for the initiative, working alongside Americans for Ibogaine Executive Director Bryan Hubbard to advance the proposal after earlier efforts in Kentucky stalled. Supporters argue that state-backed research could accelerate scientific understanding of ibogaine while positioning Texas at the forefront of potential therapeutic development.